DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

SMALL GRANTS PROGRAM FOR CRYSTALLIZATION OF MEMBRANE TRANSPORT SYSTEMS RELEVANT TO INHERITED METABOLIC DISORDERS ........................................1
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

SMALL GRANTS ON SOMATIC CELL TRANSFER OF GENES ASSOCIATED WITH SPECIFIC METABOLIC AND ENDOCRINE DISEASES ........................................3
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

THE GENETIC AND METABOLIC DEFECTS UNDERLYING CYSTIC FIBROSIS (RFA) ...............4
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES

ONGOING PROGRAM ANNOUNCEMENTS

NIAID IMMUNOLOGIC AND INFECTIOUS DISEASES ACADEMIC AWARD (K07) .................7
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES

ERRATUM

BALLOON VALVULOPLASTY REGISTRY/CLINICAL COORDINATING CENTER (RFP) - REVISION .................9
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
INTRODUCTION AND SCOPE

The Metabolic Diseases Research Program and the Cystic Fibrosis Research Program (Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK) support basic research projects related to the etiology, pathogenesis, diagnosis, treatment, and prevention of inherited metabolic disorders and cystic fibrosis. These Programs encourage researchers, experts in crystallization of membrane proteins to submit short applications for pilot projects to crystallize membrane transport systems or their components. Systems proposed for study must have relevance to understanding transport defects in diseases such as cystic fibrosis.

This line of research is suggested by recent findings that the abnormally high concentrations of sodium and chloride ions which characterize the sweat of CF patients are the result of defective reabsorption of chloride ions in duct cells of the sweat glands. Closer examination of the defective reabsorption process at the level of membrane ion channel transport proteins should prove useful in furthering our understanding of related derangements in cystic fibrosis.

Also, recent progress in crystallization of integral membrane proteins facilitates the difficult task of characterizing complete membrane ion channel transport systems or their components. The ultimate goal of resolving protein crystal structures by x-ray diffraction studies can now be reached more rapidly due to availability of the new area detectors for analysis of diffraction data.

This small grants program is intended to stimulate the development of techniques for crystallization of integral membrane proteins and their application to the study of membrane transport in health or disease. These studies could improve our understanding of the defect in cystic fibrosis and possibly other disorders of transport such as cystinosis or the muscular dystrophies. Preliminary data obtained from such pilot projects could also strengthen a subsequent application for regular grant support further pursue promising opportunities.

OBJECTIVES

This program is intended to encourage experienced investigators to submit small grant applications proposing research:

- on transport protein-detergent interactions, during solubilization, reconstitution, and crystallization of pure proteins from appropriate cell membranes;
- to crystallize appropriate membrane transport systems or their components;
- to characterize crystallized membrane transport proteins;
- to produce required quantities of purified membrane transport proteins. This should be proposed only if necessary in support of (1) and (2) and only if documented expertise in purification of membrane proteins can be secured in house or through collaboration. Approaches, such as those including recombinant DNA techniques, that could yield a sufficient amount of a novel transport system with minimal biochemical preparation are encouraged.

The emphasis should be on eukaryotic membranes; however, appropriate prokaryotic model systems with relevance to human transport diseases can be proposed for study.

ELIGIBILITY

The applicant (investigator) must be an independent researcher in the field of protein crystallization with a significant publication record.

Submission of an application under this announcement precludes concurrent submission of a regular research grant application containing the same research proposal. In addition, small grant research support may not be used to supplement research projects currently supported by Federal or non-Federal funds, or to provide interim support of projects under review by the Public Health Services.
All applicants must have received a Ph.D., M.D., or equivalent degree from an accredited domestic or foreign institution and must have had at least three subsequent years of relevant research experience. Demonstrated research ability is evidenced by prior or present grant support and publication record.

PURPOSE AND TERMS OF THE AWARD

This award will be for a period of two years. It will provide a maximum of $25,000/year in total direct costs for technical personnel directly involved in the experimental work and for supplies.

APPLICATION AND REVIEW PROCEDURES

The format for preparing this abbreviated (about 3 page) application is different from that used for regular research project grants. THEREFORE, BEFORE PREPARING AN APPLICATION, PROGRAM STAFF (listed below) MUST BE CONTACTED REGARDING SPECIAL INSTRUCTIONS. Applications must adhere to this format to be responsive and should be submitted on Form PHS 398, available at most institutional business offices or from the Division of Research Grants, NIH. A single reply date of March 2, 1987 will be strictly enforced. An anticipated schedule for review and award is detailed below:

<table>
<thead>
<tr>
<th>Application Receipt Date</th>
<th>NIDDK Special Initial Review Committee</th>
<th>Earliest Award Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2, 1987</td>
<td>March/May 1987</td>
<td>August 1987</td>
</tr>
</tbody>
</table>

REVIEW CRITERIA

A special NIDDK review committee will evaluate the scientific merit of the application based on the following criteria: soundness of the research plan; relevance of the proposed studies to understanding the defect in inherited diseases of membrane transport such as cystic fibrosis and others; the investigator's background and experience; adequacy of the research facilities; and adequacy of the justification for budget requests.

REPORTING REQUIREMENTS

If an award is made in response to a Small Grant application, a Final Progress Report, an Invention Statement and a Financial Status Report must be submitted within ninety days after the termination of the award. This final reporting requirement is the same as that for other types of research grants and is in accord with 42 CFR 52 and 45 CFR 74. This information will be especially helpful to the program in evaluating the usefulness of this Small Grant Award Mechanism.

CONSULTATION WITH PROGRAM STAFF

Prospective applicants are strongly encouraged to discuss their ideas with Program staff (see below) to determine whether they fit the definition and guidelines of this announcement. Applications which, in the opinion of staff, do not meet these objectives, scope and eligibility criteria will be returned without review. For further information and special instructions for the preparation of an application prospective applicants should contact:

Nancy Lamontagne, Ph.D.  Robert Katz, Ph.D.
Director, Cystic Fibrosis  Director, Metabolic Research Programs
Diseases Research Program  National Institutes of Health
Westwood Building, Room 607A  5333 Westbard Avenue
National Institutes of Health  Bethesda, Maryland 20892
5333 Westbard Avenue  Telephone: (301) 496-7997
Bethesda, Maryland 20892 This program is described in the Catalog of Federal Domestic Assistance, No. 13.847, Diabetes, Endocrinology, and Metabolic Diseases. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301, (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.
SMALL GRANTS ON SOMATIC CELL GENE OF GENES ASSOCIATED WITH SPECIFIC METABOLIC AND ENDOCRINE DISEASES

P.T. 34; K.W. 0715135, 1002008, 1002019, 1002027, 1003002, 0755040, 0760015

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date: March 2, 1987

INTRODUCTION AND SCOPE

The Division of Diabetes, Endocrinology and Metabolic Diseases supports basic and clinical research and research training related to diabetes mellitus and its complications, to endocrinology and a variety of endocrine disorders, and to metabolism and various metabolic diseases, including cystic fibrosis. One important area of research supported by the Division includes studies relevant to understanding the molecular and cellular mechanisms of inherited or acquired metabolic and endocrine diseases. This program is intended to encourage geneticists, molecular biologists, biochemists, microbiologists, and other qualified scientists who are supported by NIH, to submit small grant applications which propose innovative and/or high risk basic studies to further the understanding of somatic cell gene transfer in mammalian cells and its application to the therapy of inherited metabolic and endocrine diseases, including diabetes.

OBJECTIVES:

This program is intended to stimulate experienced investigators to undertake innovative and/or high risk basic research to:

- develop more efficient and more rapid approaches to chromosomal localization of genes associated with inherited metabolic and endocrine diseases, including diabetes
- identify and characterize retroviral and other vectors suitable for gene transfection of genes associated with inherited metabolic and endocrine diseases
- develop efficient methodologies for transfection of genes associated with inherited metabolic and endocrine diseases
- study the regulation of transfected and expressed genes associated with inherited metabolic and endocrine diseases
- develop techniques for homologous recombination between an incoming gene associated with inherited metabolic and endocrine diseases and its counterpart in the mammalian host genome
- identify gene products, related to the HLA region of chromosome 6 and elucidate their biological functions in diabetes.

ELIGIBILITY

Independent, established researchers who are Principal Investigators on at least one active NIH research grant award (R01) or Project Directors on a component of an active NIH program project grant (P01) or Principal Investigators on a resource grant from the NIH Division of Research Resources, may submit a small grant application in response to this solicitation.

Submission of an application under this announcement precludes concurrent submission of a regular research grant application containing the same research proposal. In addition, small grant research support may not be used to supplement research projects currently supported by Federal or non-Federal funds, or to provide interim support of projects under review by the Public Health Services.

If the applicant proposes research which will constitute a doctoral dissertation for a graduate student (other than the Principal Investigator), a written statement from the dissertation chairperson or equivalent academic supervisor to document that the proposed project has his/her approval must accompany the application. If the proposal is selected for support under this program, a statement of approval of the full dissertation committee is required before funding begins.

PURPOSE AND TERMS OF THE AWARD

This is a one-year, non-renewable award intended to provide up to $30,000 (total direct costs) for the support of technical personnel and supplies essential for the conduct of the proposed research. Awards will be made dependent on favorable review and contingent on the availability of funds.
APPLICATION AND REVIEW PROCEDURES

The format for preparing this abbreviated application (about 3 pages) is different from that used by NIH for regular research project grants. THEREFORE, BEFORE PREPARING AN APPLICATION, PROGRAM STAFF (listed below) MUST BE CONTACTED REGARDING SPECIAL INSTRUCTIONS. Applicants must adhere to this proposed format to be responsive and applications should be submitted on PHS Form 398, available at most business offices or from the Division of Research Grants, NIH. The single receipt date, March 2, will be strictly enforced. The anticipated schedule for review and award is detailed below.

| Application Receipt Date | NIDDK Special Initial Review Committee Earliest Award Date |
|--------------------------|-----------------------------------------------|------------------|
| March 2, 1987           | March/May 1987                               | August 1987      |

REVIEW CRITERIA

A special NIDDK review committee will evaluate the scientific merit of the application based on the following criteria: the significance of a successful outcome to our understanding of somatic cell gene transfer and therapy; the degree to which the project may be characterized as innovative and/or high-risk; the appropriateness and adequacy of proposed methodology, including choice of experimental material; the investigator's background and experience; adequacy of the available facilities; and the adequacy of justifications presented for budget requests.

Innovative projects are defined as being unusually imaginative or representing a markedly different approach to a problem.

High risk projects are those for which success is highly uncertain but which, if successful, would constitute an important breakthrough.

REPORTING REQUIREMENTS

If an award is made in response to a small grant application, a Final Progress Report, an Invention Statement and a Financial Status Report must be submitted within ninety days after the termination of the award. This final reporting requirement is the same as that for other types of research grants and is in accord with 42 CFR 52 and 45 CFR 74. This information will be especially helpful to the Program in evaluating the usefulness of this small grant award mechanism.

CONSULTATION WITH PROGRAM STAFF

Prospective applicants are strongly encouraged to discuss their ideas with Program staff (see below) to determine whether they fit the definition and guidelines of this announcement. Applications which, in the opinion of staff, do not meet the objectives, scope and eligibility criteria will be returned without review. For further information and special instructions for the preparation of an application prospective applicants should contact:

Robert Katz, Ph.D.  Robert Tolman, Ph.D.
Director, Metabolic Diseases  Director, Endocrinology
Research Program, NIDDK  Research Program, NIDDK
Room 607, Westwood Bldg.  Room 605, Westwood Bldg.
NTH, Bethesda, MD 20892  NIH, Bethesda, MD 20892
Telephone: (301) 496-7997  Telephone: (301) 496-7504

Julia Freeman, Ph.D.
Director, Diabetes
Research Program, NIDDK
Room 626, Westwood Bldg.
NTH, Bethesda, MD 20892
Telephone: (301) 496-7731

This program is described in the Catalog of Federal Domestic Assistance, No. 13847, Diabetes, Endocrinology, and Metabolic Diseases. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301, (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.
THE GENETIC AND METABOLIC DEFECTS UNDERLYING CYSTIC FIBROSIS

RFA AVAILABLE: 87-DK-02

P.T. 34; K.W. 0715135, 0755030, 0760025, 0760050, 1002058, 0765035

National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date: March 16, 1987

PURPOSE

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research grant applications to define and characterize the basic metabolic defect(s) associated with the etiology and pathogenesis of cystic fibrosis (CF).

BACKGROUND

Within NIDDK, the Cystic Fibrosis Research Program is a part of the Division of Diabetes, Endocrinology, and Metabolic Diseases. The present one-time solicitation is intended to augment the ongoing program by providing a special incentive for investigators to address questions related to the etiology and pathogenesis of CF.

Cystic fibrosis has long been known to be the result of a defective gene, which is inherited in an autosomal recessive manner. The CF gene has recently been located to the middle third of the long arm of chromosome 7, in a region of about one million DNA base pairs. Research efforts are now focused on identifying the CF gene and the protein encoded by this gene, enabling the detection of asymptomatic carriers. It is hoped that isolation of the defective gene responsible for CF will lead to elucidation of the underlying biochemical defect.

It is now recognized that CF is a disease of epithelial tissue and that an alteration in Cl transport across CF epithelia may be the cause of the in vitro biophysical and biochemical phenomena and the clinical manifestations associated with CF. Attention is now being focused on the intracellular regulatory pathways that couple external signals such as hormones and neurotransmitters to ion channels, pumps and carriers. Thus the level of understanding of the basic mechanism for salt transport in normal and CF epithelia have approached the stage where understanding of its relationship to the primary CF defect and the CF gene product(s) is within each.

OBJECTIVES

It is the intention of the NIDDK to facilitate research on the CF defect by increased funding of:

- Studies leading to the identification of the CF defect(s) at the genetic or biochemical level;
- Investigations directly focused on the primary expression of the genetic defect(s);
- Studies which focus on the relation between the expression of the genetic defect and the development of characteristic pathology; and
- Studies of normal structure and/or function which may be directly relevant to the primary defect(s) and its expression in CF.

SCOPE

The following list represents examples of areas of investigation responsive to this announcement:

- Identification and characterization of genetic markers related to CF;
- Identification of the CF gene(s) and characterization of the CF gene(s) at the molecular level;
- Identification and characterization of the CF gene(s) products;
- Description of fluid and electrolyte transport phenomena in normal and CF epithelial tissues;
- Identification of basic mechanisms by which the primary CF defect(s) alters physiological properties.
In cases where the research proposed does not include studies involving CF material (e.g., studies of electrolyte transport in normal epithelia), the applicant must make clear the relevance of the work to CF. Applications failing in this regard will be judged unresponsive.

MECHANISM OF SUPPORT

The mechanism of support for this program will be the grant-in-aid. The regulations (Code of Federal Regulations, Title 42, Part 52 and as applicable to the state and local governments, Title 45, Part 74) and policies which govern the research grant programs of the National Institutes of Health (NIH) will prevail. Although this solicitation is included in the funding plans for Fiscal Year 1988 for NIDDK, support is contingent upon receipt of appropriated funds for this purpose. The NIDDK plans to designate a total of $750,000 for the support of applications submitted in response to this solicitation; however, the specific amount to be funded will depend upon the overall merit and scope of the applications received. It is anticipated that approximately 8 to 10 grants will be awarded under this solicitation. Since a variety of approaches would represent valid responses to this solicitation, it is anticipated that there will be a range of costs among individual grants awarded. With respect to post-award administration, the current policies and requirements that govern the regular research grant programs of the NIH will prevail.

REVIEW PROCEDURES AND CRITERIA

Assignment of Applications

Upon receipt, applications will be reviewed by staff for their responsiveness to the objectives of this RFA. If an application is considered unresponsive, the applicant will be contacted and given an opportunity to withdraw the application or have it considered for the regular grant program of the NIH. If an application submitted in response to this RFA is identical to a research grant application already submitted to the NIH for review, the applicant will be asked to withdraw the pending application before the new one is accepted. Simultaneous submission of identical applications in response to this RFA and to the regular NIH grant program will not be allowed.

Review Procedures

Applications in response to this solicitation will be reviewed on a nationwide basis and in accord with the usual NIH peer review procedures. Applications will first be reviewed for scientific and technical merit by an Initial Review Group, which will be arranged by the Review Branch, Division of Extramural Activities, NIDDK. This group will be composed primarily of non-federal scientific consultants. The applications will then be reviewed by the National Advisory Council of NIDDK.

Review Criteria

The factors to be considered in the evaluation of scientific merit of each application will be similar to those used in the review of traditional research project grant applications, including the novelty, originality, and feasibility of the approach; the training, experience, and research competence of the investigator(s); the adequacy of the experimental design; the suitability of the facilities; and the appropriateness of the requested budget to the work proposed.

METHODS OF APPLYING

Letter of Intent

Prospective applicants are encouraged to submit a one-page letter of intent, which includes a brief synopsis of the proposed research and identification of all participating institutions, to program staff listed under INQUIRIES. Such letters are requested only for the purpose of obtaining an indication of the number and scope of applications to be received. A letter of intent is not binding, and it will not enter into the review of the application subsequently submitted. This letter should be received no later than February 17, 1987, and should be sent to: Dr. Nancy Lamontagne at the address below.
Format for Applications

Applications should be submitted on form PHS 398, which is available from an applicant institution's Office of Sponsored Research or from the NIH Division of Research Grants. Use the conventional format for research project grant applications and ensure that the points identified in this announcement are fulfilled. To identify the application as a response to this RFA, check "yes" on item two of page one of the application and enter the title "The Genetic and Metabolic Defects Underlying Cystic Fibrosis" and the RFA Number.

As in the case with regular research project grant applications, applicants are requested to furnish their own estimates of the time required to achieve the objectives of the proposed research project. However, except under very unusual circumstances, applications submitted in response to this solicitation should not request support for more than a three-year period. At the end of the initial award period, renewal applications may be submitted for further competitive review through the regular research grant program of the NIH.

Application Procedure

The original and four copies of the application should be sent or delivered to:

Application Receipt
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20892

Timetable

A letter of intent should be submitted no later than February 15, 1987. Applications must be received by March 15, 1987. Any applications not received by this date will be considered ineligible for this special solicitation.

<table>
<thead>
<tr>
<th>APPLICATION RECEIPT</th>
<th>INITIAL REVIEW</th>
<th>COUNCIL REVIEW</th>
<th>EARLIEST START DATE</th>
</tr>
</thead>
</table>

Inquiries

For further information, investigators are encouraged to contact the following office:

Nancy Lamontagne, Ph.D.
Director, Cystic Fibrosis Program
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 607
Bethesda, MD 20892
Telephone: (301) 496-4980

Two additional copies of the application are to be sent to:

Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases, NIH
Westwood Building, Room 406
Bethesda, MD 20892

This program is described in the Catalog of Federal Domestic Assistance No. 13.847, Diabetes, Endocrinology, and Metabolism. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
ONGOING PROGRAM ANNOUNCEMENTS

NIAID IMMUNOLOGIC AND INFECTIOUS DISEASES ACADEMIC AWARD (K07)

P.T. 34; K.W. 0715125, 0710070, 0715220, 0745020, 0745055, 0415000, 0785165, 0715120

National Institute of Allergy and Infectious Diseases

Application Receipt Dates: February 1, June 1, October 1

The National Institute of Allergy and Infectious Diseases (NIAID) announces the availability of the Immunologic and Infectious Diseases Academic Award (IIDAA). NIAID previously limited academic awards to the allergic diseases utilizing the Allergic Diseases Academic Award, which now is being replaced by the more broadly based IIDAA. This program is intended to assist the development of investigators and teachers in the diagnosis, treatment, prevention, pathogenesis and control of infectious diseases with emphasis on the sexually transmitted diseases (STDs), Acquired Immunodeficiency Syndrome (AIDS), or asthma, allergic, and other immunologic diseases.

The present IIDAA mechanism reflects the Institute's continuing efforts to identify and assess areas of need and to target resources among the numerous problems under the preview of NIAID. Infectious diseases represent the most frequent cause of morbidity in the U.S. and the most frequent cause of mortality worldwide. Of these, the STDs, excluding AIDS, account for $2.5 billion annually in health care costs and medication. In the most comprehensive study of the cost of AIDS to date, the cost of hospitalization and lost income for the first 10,000 cases is estimated to exceed $6 billion, and total costs will increase rapidly with increasing numbers of cases. Allergies and asthma affect 40 million in the U.S. population with an estimated cost per year of $4 billion.

Many successes have been realized in developing drugs and biologic products such as antimicrobial agents, vaccines, monoclonal antibodies, drugs that block the arachidonate cascade, and lymphokines, among others. However, the paucity of clinical research scientists in STD and allergic and immunological diseases has become a matter of concern to both Congress and the scientific community. The present IIDAA announcement represents an effort by NIAID to address this problem.

The IIDAA is intended to provide well trained clinical investigators of demonstrated superior potential with the opportunity:

1. to develop the requisite knowledge, experience and skills for academic positions and
2. concurrently, to develop the leadership needed to initiate or increase the study, care and teaching of infectious diseases, particularly STDs and/or AIDS, or allergic and immunologic diseases, in participating academic institutions.

Candidates should have a health professional degree in the clinical sciences (M.D. or D.O.) and 5 to 10 years of postdoctoral experience. Consideration will be accorded candidates whose experiences evidence an interest in infectious diseases with a concentration on the STDs or AIDS, or in allergic and immunologic diseases. In addition, broad training and demonstrated competence in the subject areas of basic and/or clinical research, teaching, and patient management are necessary to satisfy program requirements. The award is not intended for untried investigators or for productive, fully independent investigators with significant numbers of publications.

Awards will provide support for up to five (5) years, cannot be renewed but can be transferred from the original to a new grantee institution upon agreement of NIAID and the institutions. The number of awards made each year will depend on the availability of funds.

The Awardee will be provided salary support from the grant appropriate for the level of his/her academic rank at the grantee institution, up to a maximum of $40,000 annually for the period of the award. Candidates must indicate a commitment of at least 50 percent effort (not necessarily 50 percent salary) to research under the IIDAA grant, although full time is desirable. Grant applications will be reviewed for technical merit by an initial review group convened by NIAID.
Potential applicants are advised to review the program guidelines prior to completing the application form. For a copy of the guidelines, contact:

Dr. William E. Bennett  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Westwood Building, Room 7A03  
Bethesda, MD 20892

Applications should be submitted on form PHS 398 which is available in the grants and contracts business office of most academic and research institutions or from the Division of Research Grants (DRG, NIH). In space #2 on the first page of this form, indicate the title of this program announcement. The original and six copies of the application should be submitted to:

Grant Application Receipt  
Division of Research Grants  
National Institutes of Health  
Westwood Building, Room 240  
Bethesda, MD 20892

This program is described in the Catalog of Federal Domestic Assistance No. 13.885, Immunology, Allergic and Immunologic Diseases Research and No. 13.856, Microbiology and Infectious Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410; as amended; 42 USC 241) and administered under PHS grant policies and Federal regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ERRATUM

BALLOON VALVULOPLASTY REGISTRY/CLINICAL COORDINATING CENTER - REVISION

RFP AVAILABLE: RFP-NHLBI-HV-87-03

P.T. 34; K.W. 1010013, 1004008

National Heart, Lung, and Blood Institute

The National Heart, Lung, and Blood Institute (NHLBI) announcement which previously appeared in the NIH Guide for Grants and Contracts for an organization to function as a Data Coordinating Center during the five year period from June 1987 to June 1992 to collect, edit, store, and analyze baseline and outcome data on patients with severe valvular stenosis treated with balloon valvuloplasty at various participating centers is hereby amended as follows: (1) The estimated date of availability of RFP NHLBI-HV-87-03 is changed from on or about November 25, 1986 to on or about December 19, 1986; (2) The proposal due date is changed from on or about January 12, 1987 to on or about February 3, 1987; and (3) This acquisition may be a small business set-aside.

Request for copies of the RFP should include 3 self-addressed mailing label and should be sent to the following address:

(KNOTE: prior requestors need not request again)

Kristee M. Ryman, Contract Specialist  
HVD Contracts Section, Contracts Operations Branch, DEA  
National Heart, Lung, and Blood Institute  
Federal Building, Room 4C04  
National Institutes of Health  
7550 Wisconsin Avenue  
Bethesda, Maryland 20892